1. |
Woo HY, Choi JY, Yoon SK, et al. Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. Clin Mol Hepatol, 2014, 20(2):168-176.
|
2. |
Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B:a nationwide cohort study. Gastroenterology, 2014, 147(1):143-151.
|
3. |
Jang W, Yu SI, Sinn DH, et al. Longitudinal change of liver stiffness by transient elestography in chronic hepatitis B patients treated with nucleos(t)ide analogue. Clin Res Hepatol Gastroenterol, 2014, 38(2):195-200.
|
4. |
Kim YJ, Kim K, Hwang SH, et al. Durability after discontinuation of nucleos (t) ide therapy in chronic HBeAg negative hepatitis patients. Clin Mol Hepatol, 2013, 19(3):300-304.
|
5. |
Zoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut, 2013, 62(5):760-765.
|
6. |
Edge SB, Compton CC. The American Joint Committee on Cancer:the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010, 17(6):1471-1474.
|
7. |
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
|
8. |
郝捷, 陈万青.中国肿瘤登记年报(2012).北京:军事医学科学出版社, 2012:27-60.
|
9. |
戴朝六, 赵阳.原发性肝癌的综合治疗.中国普外基础与临床杂志, 2014, 21(2):133-137.
|
10. |
Yang T, Lin C, Zhai J, et al. Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging. J Cancer Res Clin Oncol, 2012, 138(7):1121-1129.
|
11. |
Piñero F, Mendizabal M, Casciato P, et al. Is recurrence rate of incidental hepatocellular carcinoma after liver transplantation similar to previously known HCC? towards a predictive recurrence score. Ann Hepatol, 2014, 13(2):211-218.
|
12. |
Kawanaka M, Nishino K, Nakamura J, et al. Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy. Liver Cancer, 2014, 3(1):41-52.
|
13. |
Sohn W, Paik YH, Kim JM, et al. HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma. Ann Surg Oncol, 2014, 21(7):2429-2435.
|
14. |
Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy:a systematic review. J Hepatol, 2010, 53(2):348-356.
|
15. |
Hosaka T, Suzuki F, Kobayashi M, et al. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int, 2010, 30(10):1461-1470.
|
16. |
Huang G, Lau WY, Wang ZG, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma:a randomized controlled trial. Ann Surg, 2015, 261(1):56-66.
|
17. |
Cheung YS, Chan HL, Wong J, et al. Elevated perioperative transaminase level predicts intrahepatic recurrence in hepatitis B-related hepatocellular carcinoma after curative hepatectomy. Asian J Surg, 2008, 31(2):41-49.
|
18. |
Hung IF, Poon RT, Lai CL, et al. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol, 2008, 103(7):1663-1673.
|
19. |
Kim BK, Park JY, Kim do Y, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int, 2008, 28(3):393-401.
|
20. |
Wong JS, Wong GL, Tsoi KK, et al. Meta-analysis:the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther, 2011, 33(10):1104-1112.
|
21. |
Kuzuya T, Katano Y, Kumada T, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol, 2007, 22(11):1929-1935.
|
22. |
Li N, Lai EC, Shi J, et al. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol, 2010, 17(1):179-185.
|
23. |
Hosaka T, Suzuki F, Kobayashi M, et al. Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. Hepatol Res, 2010, 40(2):145-152.
|
24. |
Eun JR, Lee HJ, Kim TN, et al. Risk assessment for the development of hepatocellular carcinoma:according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virusrelated liver disease. J Hepatol, 2010, 53(1):118-125.
|
25. |
Vilarinho S, Calvisi DF. New advances in precision medicine for hepatocellular carcinoma recurrence prediction and treatment. Hepatology, 2014, 60(6):1812-1814.
|
26. |
Kim MN, Han KH, Ahn SH, et al. Prevention of hepatocellular carcinoma:beyond hepatitis B vaccination. Semin Oncol, 2015, 42(2):316-328.
|